CXCR4 and pulmonary arterial hypertension: While the small-molecule CXCR4 inhibitor AMD3100 (Plerixafor) prevents pulmonary arterial muscularization in several PAH models [12, 15–17], efficacious alternative CXCR4 inhibitors for PAH treatment are scarce.